Due to a more favourable environment, BIOTIME INCO. slightly increases to Slightly Negative
BIOTIME INCO. (US), a company active in the Biotechnology industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as risky. At the fundamental level, theScreener confirms the rating of 0 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Slightly Negative even if it remains under pressure. As of the analysis date June 18, 2019, the closing price was USD 1.10 and its target price was estimated at USD 0.71.BioTime is a clinical-stage biotechnology company targeting degenerative diseases. The company's programs are based on two main proprietary technology platforms: cell replacement and cell/drug delivery. With its cell replacement platform, the company is creating new cells and tissues with its pluripotent and progenitor cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases. The company's cell/drug delivery programs are based upon its proprietary HyStem? cell and drug delivery matrix technology. HyStem? is designed to provide for the transfer, retention, engraftment and metabolic support of cellular replacement therapy.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.